A novel humanized anti-CTLA-4 antibody compared to ipilimumab in preclinical studies.

被引：1
|
作者：
Shi, Qian
Liu, Yanli
Yang, Lan
Ma, Hongli
Ma, Wencui
Sun, Ziyong
机构：
[1] CBT Pharmaceut, Pleasanton, CA USA
[2] Crown Biosci Taicang Inc, Taicang, Jiangsu, Peoples R China
[3] Crown Biosci, Taicang, Jiangsu, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 08期
关键词：
D O I：
10.1200/JCO.2019.37.8_suppl.32
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
32
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
    Lipson, Evan J.
    Drake, Charles G.
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (22) : 6958 - 6962
  • [2] Neutropenia in a Patient Treated With Ipilimumab (anti-CTLA-4 Antibody)
    Akhtari, Mojtaba
    Waller, Edmund K.
    Jaye, David L.
    Lawson, David H.
    Ibrahim, Ramy
    Papadopoulos, Nicholas E.
    Arellano, Martha L.
    [J]. JOURNAL OF IMMUNOTHERAPY, 2009, 32 (03) : 322 - 324
  • [3] A novel anti-CTLA-4 antibody with potent anti-tumor activity emerged using humanized CTLA-4 mouse model
    Guo, Chaoshe
    Yang, Yi
    Li, Zhihong
    Li, Yanan
    Chen, Yunyun
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [4] Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody
    Hodi, F. S.
    Hoos, A.
    Ibrahim, R.
    Chin, K.
    Pehamberger, H.
    Harmankaya, K.
    O'Day, S.
    Hamid, O.
    Humphrey, R.
    Wolchok, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] RBC Autoantibodies Associated with Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody that Inhibits Immune Tolerance
    Sherbeck, J.
    Cooling, L.
    [J]. TRANSFUSION, 2014, 54 : 170A - 170A
  • [6] Crystal Structure of the Fab Fragment of an Anti-CTLA-4 Antibody, Ipilimumab, Used for Cancer Immunotherapy
    Lee, Ju Yeon
    Lee, Hyun Tae
    Lee, Sang Hyung
    Lim, Heejin
    Heo, Yong-Seok
    [J]. BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 2019, 40 (06) : 582 - 585
  • [7] Review: Anti-CTLA-4 antibody ipilimumab: Case studies of clinical response and immune-related adverse events
    Weber, Jeffrey
    [J]. ONCOLOGIST, 2007, 12 (07): : 864 - 872
  • [8] PK-PD modelling of an anti-CTLA-4 antibody on immune checkpoint humanized mice
    Lee, Madeline
    Xiang, Jie
    Gan, Tian
    Shen, Yuelei
    Guo, Chaoshe
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [9] MODELING AND SIMULATION BASED EVIDENCE OF CLINICAL ACTIVITY FOR IPILIMUMAB, A NOVEL ANTI-CTLA-4 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED MELANOMA
    Dai, G.
    Masson, E.
    Wu, C.
    Berman, D.
    Pfister, M.
    Roy, A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S58 - S59
  • [10] Preclinical characterization of novel anti-CTLA-4 prodrug antibodies with an enhanced therapeutic index
    Engelhardt, John
    Akter, Rahima
    Loffredo, John
    Bezman, Natalie
    So, Paula
    Tipton, Kimberly
    Irving, Bryan
    West, James
    Freebern, Wendy
    Bunch, Todd
    Price, Karen
    [J]. CANCER RESEARCH, 2020, 80 (16)
12345